Notably, CD301 ligands emerge as prognostic markers in triple-negative breast cancer, and LSECtin ligands show promise in tumors that pose challenges in prediction and therapeutic decision-making (Mitra and Dey 2015). This evidence concerns the gene CLEC10A and triple-negative breast carcinoma.